# Biogen clinical trials: 512 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 512 trials with Biogen as lead sponsor, 22 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Biogen: 512 rows for $25.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/biogen

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 512
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 25 newest of 512, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939802 | A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis... | Biogen | Phase 2 | Not yet recruiting | Generalized Myasthenia Gravis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939802) |
| October 22, 2026 | NCT07889362 | A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Phase 2 | Not yet recruiting | Immunoglobulin A Nephropathy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889362) |
| October 21, 2026 | NCT07887828 | A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World | Biogen | Observational | Not yet recruiting | Friedreich's Ataxia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887828) |
| October 2, 2026 | NCT07855211 | A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Biogen | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855211) |
| July 23, 2026 | NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old | Biogen | Phase 2 | Recruiting | Graves' Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722546) |
| June 23, 2026 | NCT07662148 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages... | Biogen | Phase 1 | Recruiting | Healthy Volunteer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662148) |
| March 19, 2026 | NCT07483632 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric... | Biogen | Phase 3 | Not yet recruiting | Relapsing Forms of Multiple Sclerosis | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483632) |
| March 3, 2026 | NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have... | Biogen | Phase 3 | Enrolling by invitation | Antibody-mediated Rejection, Microvascular Inflammation | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444489) |
| March 3, 2026 | NCT07444476 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular... | Biogen | Phase 3 | Recruiting | Spinal Muscular Atrophy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444476) |
| March 3, 2026 | NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were... | Biogen | Phase 3 | Recruiting | Muscular Atrophy, Spinal | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444450) |
| February 10, 2026 | NCT07398469 | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone | Biogen | Observational | Recruiting | Postpartum Depression | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398469) |
| December 22, 2025 | NCT07297199 | A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn... | Biogen | Phase 1 | Completed | Healthy Volunteer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297199) |
| December 2, 2025 | NCT07259980 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic... | Biogen | Observational | Recruiting | Amyotrophic Lateral Sclerosis | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07259980) |
| November 6, 2025 | NCT07225517 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants | Biogen | Phase 1 | Recruiting | Healthy Volunteer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225517) |
| November 3, 2025 | NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis... | Biogen | Phase 4 | Active not recruiting | Amyotrophic Lateral Sclerosis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223723) |
| October 28, 2025 | NCT07221669 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With... | Biogen | Phase 3 | Recruiting | Muscular Atrophy, Spinal | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221669) |
| October 21, 2025 | NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular... | Biogen | Phase 2 | Recruiting | Microvascular Inflammation | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219043) |
| September 2, 2025 | NCT07149415 | A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy... | Biogen | Phase 1 | Completed | Healthy Volunteer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07149415) |
| August 21, 2025 | NCT07133828 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old | Biogen | Phase 1 | Recruiting | Healthy Volunteer | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133828) |
| July 2, 2025 | NCT07047820 | A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End... | Biogen | Observational | Completed | Depression, Postpartum | 305 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047820) |
| June 13, 2025 | NCT07019064 | A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy... | Biogen | Phase 1 | Completed | Healthy Volunteer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07019064) |
| May 8, 2025 | NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Biogen | Phase 3 | Recruiting | Primary Membranous Nephropathy | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962800) |
| May 1, 2025 | NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | Biogen | Phase 3 | Active not recruiting | Friedreich Ataxia | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06953583) |
| April 20, 2025 | NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Phase 3 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06935357) |
| December 19, 2024 | NCT06741657 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways | Biogen | Phase 1 | Completed | Healthy Volunteer | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06741657) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 164 |
| Phase 1/2 | 14 |
| Phase 2 | 94 |
| Phase 2/3 | 3 |
| Phase 3 | 92 |
| Phase 4 | 42 |
| Not applicable | 6 |
| Observational | 95 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 357 |
| Terminated | 90 |
| Withdrawn | 20 |
| Recruiting | 18 |
| Active not recruiting | 17 |
| Not yet recruiting | 4 |
| Enrolling by invitation | 3 |
| No longer available | 2 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Sclerosis | 116 |
| Multiple Sclerosis, Relapsing-Remitting | 78 |
| Muscular Atrophy, Spinal | 27 |
| Arthritis, Rheumatoid | 16 |
| Alzheimer Disease | 12 |
| Recurrence | 12 |
| Crohn Disease | 11 |
| Parkinson Disease | 10 |
| Renal Insufficiency, Chronic | 9 |
| Amyotrophic Lateral Sclerosis | 9 |
| Diabetes Mellitus, Type 2 | 8 |
| Depressive Disorder, Major | 8 |
| Lymphoma, Non-Hodgkin | 8 |
| Lupus Erythematosus, Systemic | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Trigeminal Neuralgia | 6 |
| Friedreich Ataxia | 6 |
| Multiple Sclerosis, Chronic Progressive | 5 |
| Neoplasm Metastasis | 5 |
| Schizophrenia | 5 |
| Leukoencephalopathy, Progressive Multifocal | 5 |
| Choroideremia | 4 |
| Melanoma | 4 |
| Lupus Erythematosus, Cutaneous | 4 |
| Diabetic Nephropathies | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
